This move is archived. Current quotes and coverage live on the stock page.
Follow LOVE
Cannara Biotech Inc. is experiencing a downturn in its stock price, raising concerns among investors.
Cannara Biotech Inc. (LOVE.TO) is facing a tough day as its stock price has dropped by 2.07% to CA$1.89. This decline comes despite recent positive news about record revenues and profitability. Investors are left wondering why this is happening.
Advertisement
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$209.42M
P/E
19.3x
52W high
$2.37
52W low
$1.55
1W change
+1.42%
Beta
0.27
Analyst Price Targets
Based on analyst covering LOVE · as of Sep 17, 2026
Wall Street analysts forecast LOVE stock price to rise 57.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
+57.7% Upside
Current Price
C$2.14
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
27.7%
Annualized
90-Day Vol
32.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.27 | C$2.06 – C$2.50 |
| 60 trading days | C$2.41 | C$2.11 – C$2.76 |
| 90 trading days | C$2.56 | C$2.17 – C$3.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should stay cautious as Cannara Biotech's stock falls, especially since there’s no significant news explaining the downturn.
Cannara Biotech's Market Cap at CA$188.67 Million
The current market cap reflects investor sentiment, which may be influenced by today’s stock performance.
Bull case
Despite the recent slide, Cannara has reported record Q3 revenues and profitability, showing strong operational performance. This suggests that the company is doing well operationally, even if the stock price doesn't reflect it right now.
Bear case
The recent stock decline might indicate underlying issues or a disconnect between investor sentiment and the company’s positive operational metrics. Investors could be worried about what this means for the future, despite the strong numbers.
Advertisement
Recent Performance Overview
Cannara Biotech Inc. has seen its stock drop by 2.07% today, closing at CA$1.89. This performance comes even after announcements of record revenues and an expansion in distribution. Investors may be questioning whether these gains can be sustained in light of today’s drop.
Market Sentiment and Future Outlook
The current market cap of Cannara Biotech stands at CA$188.67 million, reflecting investor sentiment that seems to be wavering. While the company is making progress in revenue growth and operational efficiency, the recent stock performance suggests that investors are cautious about future prospects. Keeping an eye on market trends and company announcements will be important for investors considering whether to buy or sell.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
